The Cooper Companies, Inc. $COO Holdings Raised by Capital International Ltd. CA

Key Points

• Capital International Ltd. CA raised its stake in The Cooper Companies by 61.5% in Q3 to 114,124 shares (an additional 43,479 shares) valued at $7.82M, while other institutions including Massachusetts Financial Services and Amundi also made large purchases, leaving institutional ownership near 24.39%.
• Insider buying accelerated recently — Director Maria Rivas bought 1,000 shares and Holly R. Sheffield bought 1,230 shares, with insiders purchasing 16,014 shares (~$1.30M) over the last quarter and now owning about 2.08% of the company.
• Quarterly results: Cooper beat EPS estimates ($1.10 vs. $1.03) with revenue of $1.02B (up 6.2% YoY), set Q2 2026 guidance at 4.580–4.660 EPS, and carries a consensus analyst rating of "Moderate Buy" with an average price target of $90.79.

Capital International Ltd. CA raised its stake in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 61.5% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 114,124 shares of the medical device company's stock after buying an additional 43,479 shares during the period. Capital International Ltd. CA owned approximately 0.06% of Cooper Companies worth $7,824,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in the stock. Buckhead Capital Management LLC raised its stake in shares of Cooper Companies by 14.3% in the 3rd quarter. Buckhead Capital Management LLC now owns 58,930 shares of the medical device company's stock worth $4,040,000 after buying an additional 7,368 shares in the last quarter. First American Bank bought a new position in Cooper Companies during the third quarter valued at about $1,646,000. Rakuten Investment Management Inc. acquired a new position in shares of Cooper Companies in the 3rd quarter worth approximately $11,341,000. Amundi raised its holdings in shares of Cooper Companies by 35.5% in the 2nd quarter. Amundi now owns 1,331,480 shares of the medical device company's stock worth $97,225,000 after purchasing an additional 348,652 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in Cooper Companies by 96.9% during the third quarter. Massachusetts Financial Services Co. MA now owns 3,099,750 shares of the medical device company's stock worth $212,519,000 after buying an additional 1,525,693 shares in the last quarter. 24.39% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Maria Rivas bought 1,000 shares of the company's stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $82.13 per share, with a total value of $82,130.00. Following the acquisition, the director owned 11,141 shares in the company, valued at approximately $915,010.33. This represents a 9.86% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Holly R. Sheffield bought 1,230 shares of the stock in a transaction dated Tuesday, December 16th. The stock was purchased at an average cost of $80.75 per share, for a total transaction of $99,322.50. Following the acquisition, the insider owned 39,052 shares in the company, valued at $3,153,449. The trade was a 3.25% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last quarter, insiders have purchased 16,014 shares of company stock valued at $1,304,416. 2.08% of the stock is owned by company insiders.

Cooper Companies News Summary

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Insiders (CEO, directors and other executives) purchased shares in recent months, reinforcing management confidence in the business and complementing continuing share repurchases — a constructive signal for investors. CooperCompanies Insiders Buy as Rebound Setup Forms
• Positive Sentiment: An unnamed report raised Cooper's price target to $103, reflecting upside from current levels and highlighting bullish analyst conviction after the quarter and buyback activity. Cooper Companies NASDAQ: COO Price Target Raised to $103.00
• Neutral Sentiment: Analyst/education pieces (Zacks) reiterate Cooper as a longer-term value/quality healthcare name but flag the importance of monitoring international revenue trends — useful for longer-horizon investors but not immediate catalysts. Why The Cooper Companies (COO) is a Top Value Stock for the Long-Term
• Neutral Sentiment: Another Zacks piece recommends watching geographic/international revenue trends for their impact on estimates — informative but not an immediate driver. Investing in The Cooper Companies (COO)? Don't Miss Assessing Its International Revenue Trends
• Negative Sentiment: Citigroup reduced its price target to $87, signaling caution from some institutional analysts despite the recent earnings beat; conflicting analyst views are likely contributing to short-term selling pressure. Citigroup Cuts Cooper Companies NASDAQ: COO Price Target to $87.00

Analyst Ratings Changes

A number of brokerages recently issued reports on COO. Wells Fargo & Company lifted their target price on Cooper Companies from $72.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, December 5th. Wall Street Zen upgraded Cooper Companies from a "hold" rating to a "buy" rating in a report on Saturday, February 28th. Mizuho set a $100.00 price objective on Cooper Companies and gave the stock an "outperform" rating in a research note on Friday, December 5th. William Blair upgraded Cooper Companies to a "strong-buy" rating in a report on Friday, January 30th. Finally, Robert W. Baird raised their price target on shares of Cooper Companies from $85.00 to $98.00 and gave the stock an "outperform" rating in a report on Friday, December 5th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $90.79.

Cooper Companies Stock Performance

Shares of COO opened at $75.82 on Tuesday. The Cooper Companies, Inc. has a 12 month low of $61.78 and a 12 month high of $89.83. The company's fifty day moving average is $81.98 and its 200-day moving average is $76.02. The company has a quick ratio of 0.79, a current ratio of 1.34 and a debt-to-equity ratio of 0.22. The firm has a market cap of $14.79 billion, a price-to-earnings ratio of 37.53, a price-to-earnings-growth ratio of 2.13 and a beta of 1.02.

Cooper Companies (NASDAQ:COO - Get Free Report) last released its quarterly earnings results on Thursday, March 5th. The medical device company reported $1.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.03 by $0.07. Cooper Companies had a net margin of 9.67% and a return on equity of 10.34%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.02 billion. During the same period in the prior year, the company earned $0.92 earnings per share. The business's quarterly revenue was up 6.2% compared to the same quarter last year. Cooper Companies has set its Q2 2026 guidance at 4.580-4.660 EPS. Equities analysts expect that The Cooper Companies, Inc. will post 3.98 EPS for the current fiscal year.

Cooper Companies Company Profile

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.